Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.43 and traded as high as $1.45. Cortexyme shares last traded at $1.43, with a volume of 656,349 shares traded.
Cortexyme Stock Up 19.2%
The business’s 50-day simple moving average is $1.07 and its 200 day simple moving average is $1.43. The firm has a market capitalization of $43.12 million, a P/E ratio of -0.48 and a beta of 1.40.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Further Reading
- Five stocks we like better than Cortexyme
- What Are the U.K. Market Holidays? How to Invest and Trade
- New Catalysts to Drive NVIDIA’s Stock Price Even Higher
- What is diluted earnings per share (Diluted EPS)?
- China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Palantir Defies Bears, Leads S&P 500 in 2025
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
